Uroxatral

This page contains recent news articles, when available, and an overview of Uroxatral but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Uroxatral
(when available)

Pharmacology and use:
Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Alfuzosin results from a decrease in systemic vascular resistance and the parent compound Alfuzosin is primarily responsible for the antihypertensive activity. For the treatment of the signs and symptoms of benign prostatic hyperplasia

Mechanism Of Action:
Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

News Articles on Alfuzosin

Family Doctor: Pumpkins can be used for more than pieD  -  ‎Nov 11, 2009‎
The urologist put him on Uroxatral. He also continued to take saw palmetto and fish-oil capsules. His PSA gradually dropped to 3.7. ... Canton Repository

Uroxatral Risks Not Adequately Disclosed in Advertisements: FDA Warns  -  ‎Oct 29, 2009‎
The FDA issued a warning letter to drug maker Sanofi-Aventis over the use of certain promotional materials for its prostate drug Uroxatral, which were ... AboutLawsuits.com

FDA Warns Sanofi Over Ad For Prostate Drug >SNY  -  ‎Oct 27, 2009‎
The advertisement for Uroxatral, used to treat enlarged prostates, was a "tent card" and was presented with an outdated version of the drug's label, ... Wall Street Journal

Sanofi Uroxatral Promotion Gets Untitled Letter  -  ‎Nov 5, 2009‎
A “tent card� Sanofi-Aventis prepared to promote Uroxatral to treat benign prostatic hyperplasia presents overblown efficacy claims and should be withdrawn, ... FDA news (subscription)

Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards  -  ‎Oct 21, 2009‎
Company: Devito/Verdi -- Disease Awareness -- Uloric - Flares Aren't the Whole Story -- Company: GSW Worldwide -- Uroxatral - Uroxatral Patient Brochure ... Reuters

French and Benelux stocks - Factors to watch on Oct 28  -  ‎Oct 28, 2009‎
...the French drugmaker of distributing misleading promotional material on its Uroxatral treatment for urinary problems caused by an enlarged prostate. ... Forbes

LEAD 1 USA - Avertissement à Sanofi concernant l'Uroxatral  -  ‎Oct 27, 2009‎
PA: Cotation) qu'elle accuse d'employer du matériel promotionnel trompeur relatif à l'Uroxatral, un traitement de l'hypertrophie bénigne de la prostate. ... Reuters

FDA, 사노피 전립선비대약 우로ìž?트랄 íŒ?ì´‰ 경고  -  ‎Nov 1, 2009‎
...김윤ì˜? 기ìž? FDA는 사노피-아벤티스사ì?˜ 전립선 비대ì¦? 치료약 우로ìž?트랄(Uroxatral: alfuzosin)ì—? 대한 íŒ?촉물ì—?서 오ë?„하는 표현ì?„ ì§€ì ?하고 경고 서신ì?„ 회사ì—? ... 메디포뉴스

FDA verwarnt Sanofi-Aventis wegen Werbekarte zu "Uroxatral"  -  ‎Oct 27, 2009‎
Pharmahersteller Sanofi-Aventis verwarnt, weil in einer Werbung für das Medikament "Uroxatral" nicht auf die Risiken des Produkts hingewiesen werde. ... Finanztreff

Le Cac 40 sous les 3.700 points avant les stats américaines  -  ‎Oct 28, 2009‎
...de Sanofi-Aventis qui gagne 0,62% à 52,35 euros en dépit d'un avertissement de l'autorité sanitaire américaine pour marketing trompeur sur l'Uroxatral. ... Les Échos

Repli attendu à Paris, ArcelorMittal en première ligne  -  ‎Oct 28, 2009‎
...l'accusant de faire usage d'un marketing trompeur pour la promotion de l'Uroxatral, un traitement contre les troubles de la prostate. ... Les Échos

What Texans Should Know about Cataract Surgery  -  ‎Aug 18, 2009‎
...doctor your complete medical and eye health history, including especially whether you are or have taken Flomax(R), Hytrin(R), Uroxatral(R) or Cadura(R). PR Newswire (press release)

The hidden cost of obesity  -  ‎Jul 12, 2009‎
Simvastatin 40 mg, Uroxatral 10 mg By Marshall Allen (contact) Before you read this story, please suspend any biases you may have about fat people. Las Vegas Sun

BUYINS.NET: BLUD, NVO, RBN, ROS, SNY, CPII. Abnormal Price ...  -  ‎Jun 26, 2009‎
Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. Trading Markets (press release)

SNY-A Sanofi Safety Scare?  -  ‎Jun 26, 2009‎
Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. TransWorldNews (press release)

Sanofi-Aventis and AEterna Zentaris sign development agreement for ...  -  ‎Mar 9, 2009‎
...said: "This deal complements our strong presence in the urology space with Uroxatral (alfuzosin), Eligard (leuprolide) and Cialis (tadalafil), Trading Markets (press release)

Sanofi-aventis and AEterna Zentaris Sign Agreement in the US  -  ‎Mar 6, 2009‎
General Therapeutics Business Unit at sanofi-aventis US "This deal complements our strong presence in the urology space with Uroxatral(R) (alfuzosin), PR Newswire (press release)

Incontinence, common among elderly, can be controlled  -  Jan 15, 2009
These include terazosin (Hytrin), doxazosin (Cardura), alfuzosin (Uroxatral), and tamsulosin (Flomax). Some of the older agents in this group can decrease Great Falls Tribune,

Alpha-Blocker Therapy Shows No Benefit for Prostatitis  -  Dec 17, 2008
17 -- For chronic prostatitis-chronic pelvic pain syndrome, the alpha-blocker alfuzosin (Uroxatral) did no better than placebo, according to a randomized MedPage Today,

Researchers rip open holiday myths  -  Dec 18, 2008
The international study of the drug alfuzosin, marketed under the brand name of Uroxatral, was led by Curtis Nickel of Queen's University in Kingston. Globe and Mail,

World-Renowned Urologist, J. Francois Eid, MD, Expands Practice ...  -  Nov 21, 2008
Alpha blockers, which include Flomax, Cardura, Hytrin and Uroxatral are the most common way to treat BPH. They work by relaxing the prostate gland's smooth PR Web (press release),

Acino: Erste neun Monate 2008 mit Rekordresultat  -  Oct 30, 2008
OxyContin von Mun-dipharma), Alfuzosin (Originalpräparat: Xatral XL, UroXatral von Sanofi-Aventis) und Amlodipin (Originalpräparat: Norvasc von Pfizer). Business-News (Pressemitteilung),

BPH Drugs May Differ in Effects on Fracture Risk  -  Oct 7, 2008
Examples of selective alpha-blockers include tamsulosin (Flomax) and alfuzosin (UroXatral). The authors pointed out that "a well-known adverse effect of MedPage Today,

Mike Schmidt urges men to cover all bases when it comes to health  -  Aug 21, 2008
Schmidt went to see a urologist and was prescribed to UROXATRAL. His urination problems are now under control and he wants to educate men all over the NECN,

Tratando una próstata agrandada  -  Sep 6, 2008
...incluyendo fínasteride (Prosear) y bloqueadores alfa, incluyendo terazosín (Hytrin), doxazosín (Cardura), tamusolina (Flomax) y alfuzosin (Uroxatral). Crítica,

Treating an enlarged prostate  -  Aug 4, 2008
...including terazosin (Hytrin), doxazosin (Cardura), tamsulosin (Flomax) and alfuzosin (Uroxatral). In addition to these tried and tested medications, Abilene Reporter-News,

Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet ...  -  Aug 7, 2008
Tambocor(R); (flecainide); Uroxatral(R) (alfuzosin hydrochloride); Vascor(R) (bepridil); Versed(R) (midazolam); and Vfend(R) (voriconazole). FOXBusiness

علاج تضخم البروستاتا  -  Aug 5, 2008
مثبطات ألÙ?ا: (terazosin (Hytrin), doxazosin (Cardura), (Flomax), prazosin (Uroxatral Ù?مثبطات ألÙ?ا تحسن الأعراض ولكنها لا تقلل حجم التضخم. القبس,

US Banks' Shaky Payouts, Sanofi Strategy, UK Press: Timshel  -  Jun 19, 2008
Last week, for instance, the company filed a lawsuit accusing India's Sun Pharmaceutical Industries Ltd. of violating a US patent for Uroxatral, Bloomberg

Sanofi-Aventis Sues Sun Pharmaceutical Over Patent (Update2)  -  Jun 12, 2008
...sued Indian rival Sun Pharmaceutical Industries Ltd., alleging infringement of a US patent for Uroxatral, used to treat an enlarged prostate gland. Bloomberg

Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First ...  -  Jun 19, 2008
Together, we developed a game plan to manage my symptoms with Uroxatral(R) (alfuzosin HCl 10 mg extended-release tablets). Best known for leading the Earthtimes (press release),

Eli Lilly and Sanofi Partner on Cialis  -  May 25, 2008
Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia, and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, RedOrbit,

For Men, Relief in Sight  -  May 12, 2008
Alpha blockers like Flomax, Uroxatral, Hytrin and Cardura relax muscle fibers in the bladder and prostate. Other drugs like Proscar and Avodart, New York Times,

Skyepharma PLC - Interim Management Statement  -  May 18, 2008
This decline was more than offset by strong growth in the USA, where sales of Uroxatral® were EUR26 million (GBP20 million), up 18.2%. Market Wire (press release)

Sanofi-Aventis and Lilly in Cialis marketing pact  -  Mar 27, 2008
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years,� Sanofi-Aventis markets Uroxatral Medical Marketing and Media,

More Than Half of Patients Treated for Benign Prostatic ...  -  Apr 7, 2008
Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's PR Newswire (press release),

Brand Names/Synonyms:
Uroxatral is also known by the following brand names and/or synonyms:
Uroxatral; Xatral

Drug Category:
Uroxatral is categorized under the following by the FDA: Antihypertensive Agents; Unclassified Therapeutic Agents (92:00.00); ATC:G04CA01

Dosage Forms:
TABLET (EXTENDED-RELEASE)

Absorption:
Absorption is 50% lower under fasting conditions

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy